Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Palatin Technologies reports revenue challenges but advances pipeline programs

Palatin Technologies faced revenue challenges in Q3 2024 but showcased strengths in pipeline advancements and positive clinical results.
The company's financial performance improved despite increased operating expenses, with a focus on expanding clinical programs and enhancing drug profiles.
While facing cash utilization concerns and upcoming study expenses, Palatin remains optimistic about its progress and future milestones.

Palatin Technologies reports Q4 loss, progresses in ocular treatments

Palatin Technologies navigated Q4 2024 with a focus on cost reduction and asset sales, impacting revenue and expenses.
Despite financial challenges, the company's progress in ocular programs and pipeline development showcases strategic advancements.
Opportunities lie in leveraging asset sale proceeds, advancing clinical programs, and addressing funding needs for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.

Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?

In the latest trading session, Palatin (PTN) closed at $0.91, marking a -1.7% move from the previous day.

Palatin (PTN) Stock Sinks As Market Gains: What You Should Know

Is  (PTN) Outperforming Other Medical Stocks This Year?

Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?

Palatin (PTN) closed the most recent trading day at $1, moving +0.37% from the previous trading session.

Palatin (PTN) Gains As Market Dips: What You Should Know

A high-profile analyst questioned the company's recent FDA approval.

Why Palatin Technologies Stock Dropped as Much as 21.5% Today

Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG Pharmaceuticals Inc. treatment for hypoactive sexual desire disorder (HSDD) triggered a $60 million milestone payment.

Palatin's stock rockets after FDA OK to market sexual desire disorder treatment

The demanded phase I trial showed consistent results compared to the previous trials and AMAGs CEO is: "fairly optimistic about the approval ability" of Vyleesi.

Palatin Technologies: The Future Of Peptide Drugs

Alexion Pharma

AMAG Pharmaceuticals

Merck

Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.

3 Drug Stocks That Could Win From Key FDA Approvals in June

Palatin Technologies' (PTN) CEO Carl Spana on Q3 2019 Results - Earnings Call Transcript

ANI Pharma

Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.

Palatin Technologies (PTN) in Focus: Stock Moves 5.7% Higher

News for Palatin Technologies Stock (PTN)